ANI Pharmaceuticals Inc  

(Public, NASDAQ:ANIP)   Watch this stock  
Find more results for NASDAQ:BPAX
-3.43 (-5.44%)
After Hours: 59.62 0.00 (0.00%)
Feb 22, 4:38PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 59.30 - 62.06
52 week 30.15 - 70.92
Open 62.04
Vol / Avg. 266,117.00/115,994.00
Mkt cap 667.67M
P/E 87.76
Div/yield     -
EPS 0.68
Shares 11.58M
Beta 3.00
Inst. own 58%
Feb 21, 2017
Q4 2016 ANI Pharmaceuticals Inc Earnings Release (Estimated)
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin 6.60% 20.14%
Operating margin 20.56% 42.84%
EBITD margin - 51.89%
Return on average assets 3.25% 5.64%
Return on average equity 6.09% 10.20%
Employees 108 -
CDP Score - -


210 W Main St
BAUDETTE, MN 56623-2467
United States - Map
+1-218-6343500 (Phone)
+1-218-6343540 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company's focused areas of product development include anti-cancer (oncolytics), hormones and steroids, and complex formulations. Its generic products include Esterified Estrogen with Methyltestosterone, Etodolac, Flecainide, Fluvoxamine, Hydrocortisone Enema, Methazolamide, Metoclopramide Syrup, Nimodipine, Opium Tincture, Oxycodone Oral Solution, Propafenone and Vancomycin. Its branded products include Cortenema, Lithobid, Reglan and Vancocin. It has over two pharmaceutical manufacturing facilities located in Baudette, Minnesota that are capable of producing oral solid dose products, as well as liquids and topicals, controlled substances, and potent products. Its two facilities have a combined manufacturing, packaging and laboratory capacity totaling approximately 173,000 square feet.

Officers and directors

Robert E. Brown Jr. Chairman of the Board
Age: 64
Bio & Compensation  - Reuters
Arthur S. Przybyl President, Chief Executive Officer, Director
Age: 58
Bio & Compensation  - Reuters
Stephen P. Carey Chief Financial Officer, Vice President
Bio & Compensation  - Reuters
James G. Marken Vice President - Operations
Age: 52
Bio & Compensation  - Reuters
David J. Sullivan Ph.D. Vice President - Quality Operations
Bio & Compensation  - Reuters
Mark J. Ginski Ph.D. Vice President of Corticotropin Product Development
Bio & Compensation  - Reuters
Karen Quinn Ph.D. Vice President - Corticotropin Regulatory Affairs
Bio & Compensation  - Reuters
Robert W. Schrepfer Vice President - New Business Development and Contract Manufacturing
Age: 43
Bio & Compensation  - Reuters
Peter A. Lankau Director
Age: 62
Bio & Compensation  - Reuters
Thomas A. Penn Director
Age: 69
Bio & Compensation  - Reuters